Study
Milk Thistle Extract Shows Promise for Liver Health in Adults with NASH
In a study, milk thistle extract was found to be safe but did not significantly improve liver scores in adults with NASH.
Summary
In plain language
A recent study explored the effects of milk thistle extract, specifically silymarin, on adults with non-alcoholic steatohepatitis (NASH), a serious liver condition. Researchers aimed to see if this common herbal remedy could improve liver health in those diagnosed with NASH. While the study confirmed that taking silymarin is safe, it did not lead to a significant improvement in the liver health scores of participants. This finding is important as NASH affects a substantial portion of the population and currently lacks approved treatments. Seniors, particularly those with liver conditions, might consider discussing herbal options like silymarin with their healthcare providers.
Details
Use the full description to understand the study design, methods, and the limits of the findings.
This study was conducted as a clinical trial with participants who had non-alcoholic steatohepatitis (NASH), a liver disease associated with factors like obesity and diabetes.
It tested two doses of silymarin, a milk thistle extract, comparing them to a placebo to assess safety and effectiveness over nearly a year.
The results showed that silymarin was safe but did not significantly reduce liver damage scores compared to the placebo.
One limitation was that not all participants had confirmed NASH at study entry, which could affect results.
While silymarin was safe, seniors should talk to their healthcare providers about the best treatments for liver health.
Full Study
Open the original publication for the complete methods, outcomes, and source material.
Milk Thistle Extract Shows Promise for Liver Health in Adults with NASH
Published May 2026
Opens at the publisher · external site · may require institutional access
Research Quality Score
Scored October 22, 2026 using rubric mq-1.8_2026-07-06.
Assessment
The study scored highly on design and bias control due to its rigorous RCT methodology. Statistical integrity was strong with pre-specified endpoints and adequate power. Transparency was ensured through registration and reporting compliance. However, conflicts of interest were present due to sponsor involvement, and the study lacked external replication. The relevance score was low as the population did not align with the target seniors, and journal quality could not be assessed.
Category Breakdown
| Category | Score | Rating |
|---|---|---|
| Study design | 10.0/10 | |
| Bias control | 10.0/10 | |
| Statistical methods | 10.0/10 | |
| Reporting completeness | 10.0/10 | |
| Conflicts & funding | 5.0/10 | |
| Replication | 0.0/10 | |
| Relevance to chosen population | 0.0/10 | |
| Journal Reliability | 5.0/10 |
Additional Notes
This phase II trial evaluated the safety and efficacy of silymarin in adults with NASH. It found no significant improvement in liver histology compared to placebo, though silymarin was well tolerated.
Assessed on the study's full text across 8 quality dimensions; conflict-of-interest disclosures were reviewed.
Treatments Evaluated in This Research
Review the interventions studied here and compare them against the broader treatment library.
Take the next step
Build a personalized plan using research-backed studies, conditions, and treatments.